CI Investments Inc
IMVT icon

CI Investments Inc’s Immunovant IMVT Stock Holding History

CI Investments Inc’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-106
Closed -$3K – 1315
2024
Q4 		$3K Buy
106
+3
+3% +$85 ﹤0.01% 1290
2024
Q3 		$3K Sell
103
-1
-1% -$29 ﹤0.01% 1261
2024
Q2 		$3K Sell
104
-6
-5% -$171 ﹤0.01% 1243
2024
Q1 		$4K Buy
+110
New +$4.01K ﹤0.01% 1268

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

CI Investments Inc's IMVT Position: Q1 2025 in Review

CI Investments Inc sold out of Immunovant (IMVT) in Q1 2025, closing a stake of 106 shares — an estimated $3K sold.

CI Investments Inc first reported a position in IMVT in Q1 2024 and held it in 4 quarters. The position peaked at $4K in Q1 2024. 193 funds tracked by Wall St. Rank hold IMVT as of Q1 2025.

  • CI Investments Inc reported no remaining Immunovant position as of Q1 2025 after selling out during the quarter.
  • CI Investments Inc sold 106 Immunovant shares in Q1 2025, an estimated $3K.
  • CI Investments Inc first reported a position in Immunovant in Q1 2024 and held it in 4 quarters.
  • CI Investments Inc's Immunovant position peaked at $4K in Q1 2024.
  • 193 funds tracked by Wall St. Rank held Immunovant as of Q1 2025.

Based on CI Investments Inc's 13F filing for Q1 2025, filed 13 May 2025.